1-[3-Azabicyclo[3.3.0]oct-3-yl]-3-p-toluenesulfonylurea

Gliclazide has been used to study its antiglycative properties and to study its effects on the glycation of bovine serum albumin (BSA) structure as a reference standard in solid-phase extraction (SPE) followed by instrumental analysis using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MSMS) for the quantification of water samples as a reference standard in solid-phase extraction (SPE) followed by instrumental analysis using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MSMS) for the quantification of water samples Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. Its classification has been ambiguous as literature uses it as both a first-generation and second-generation sulfonylurea. Gliclazide was shown to protect human pancreatic beta-cells from hyperglycemia-induced apoptosis. It was also shown to have an antiatherogenic effect (preventing accumulation of fat in arteries) in type 2 diabetes.